RhoVac, a Ventac Partners portfolio company, announced that all patients in the company’s clinical phase I/II study successfully completed their treatment phase with RV001. For more information, please visit this link.
We participate in numerous events promoting our portfolio companies and meeting our clients.
RhoVac, Ventac Partners portfolio company, reports positive pre-submission meeting with the European Medicines Agency. For more information, please visit this link.